Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a phase IV, prospective, single-center, open-label, randomized, controlled study. Eligible patients are randomly assigned into three groups. The investigators propose to evaluate and compare the efficacy and safety of different neoadjuvant chemotherapies in women with primary breast cancer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tao OUYANG
• Treatments: Cyclophosphamide; Epirubicin; Fluorouracil

Criteria

Inclusion Criteria:

• Female patients, age ≦ 65 years old

• Histologically or cytologically confirmed primary breast cancer by core biopsy

• Disease stage appropriate for neoadjuvant chemotherapy (T2～T3，N0～2，M0)

• No previous treatment for breast cancer

• No history of other malignancies

• No currently uncontrolled diseased (e.g., ongoing cardiac dysrhythmias, unstable diabetes) or active infection

• No history of other malignancies

• No currently uncontrolled diseased or active infection

• Not pregnant or breast feeding, and on appropriate birth control if of child-bearing potential

• Adequate cardiovascular function reserve without a myocardial infarction within the past six month

• Adequate hematologic function with:

1. Absolute neutrophil count (ANC) ≥ 1500/mm3

2. Platelets ≥ 100,000/ mm3

3. Hemoglobin ≥ 10 g/dL

• Adequate hepatic and renal function with:

1. Serum bilirubin ≤ 1.5×UNL

2. Alkaline phosphatase and alanine aminotransferase (ALT) ≤ 2.5 x ULN.

3. Serum creatinine ≤ 1.7 mg/dl

• Knowledge of the investigational nature of the study and Ability to give informed consent

• Ability and willingness to comply with study procedures

Exclusion Criteria:

• Known or suspected distant metastases

• Concurrent malignancy or history of other malignancy

• Uncontrolled diseases or active infection

• Hepatic or renal dysfunction as detailed above

• Geographical, social, or psychological problems that would compromise study compliance

• Known or suspected hypersensitivity to cyclophosphamide, epirubicin and fluorouracil